BERLIN, June 4, 2024 /PRNewswire/ -- MGI (MGI Tech Co.,
Ltd. or its subsidiaries, together referred to MGI), a company
committed to building core tools and technologies that drive
innovation in life science, today announced the opening of its new
European headquarters in Berlin,
Germany to support the life science community across the
region.
"We chose Berlin for our
European headquarters owing to its vibrant and dynamic environment,
ensuring accessibility for partners, collaborators, and customers,"
remarked Dr. Yong Hou, General
Manager of MGI Europe and Africa.
"I eagerly anticipate the innovative collaborations and discoveries
ahead."
The new facility, conveniently located near the Berlin
Brandenburg Airport and open to external visits, features MGI's
latest products and technologies. The space spans over 600
square meters and features the company's very own Customer
Experience Center (CEC) and advanced labs, with plans for further
expansion. It will also be home to prototypes of upcoming MGI
products for early access and testing by European partners and
collaborators.
Equipped with MGI's full product portfolio, the CEC within the
new Berlin headquarters serves as
a dedicated gateway for researchers and scientists in the region to
learn about and experience the company's cutting-edge life science
innovation. Through tailored trainings, demos, and hands-on
workflow, visitors can explore the full possibilities of creating
their own innovative multi-omics tools based on the proprietary
DNBSEQ™ technology. The inaugurate initiative launched at the
CEC opening is a G400 Developer Program to support researchers in
Europe with the development and
implementation of customized workflows for spatial transcriptomic,
multiplex immunofluorescence (mIF) and other multi-omics
analysis.
Furthermore, the facility has been configured with DNA
sequencing, Cell Omics and Spatial Omics capabilities, positioned
to support novel application and project development for MGI
customers and collaborators.
Following an exceptional start of the year, MGI continues to
expand its reach and strives to better serve the life science
sector through various groundbreaking partnerships across the
region. Notably, in February, the company entered a collaboration
agreement with MetaGenoPolis in France, to equip the organization with MGI's
DNBSEQ-T7 ultra-high throughput sequencer for the "Le French Gut"
project and other research under the Million Microbiomes from
Humans Project (MMHP).
In March, MGI reached a milestone partnership with Eurofins
Genomics Europe Genotyping A/S for the first corporate order of the
revolutionary DNBSEQ-T20×2 ultra-high throughput sequencer in
Europe, paving the way for
significant advances in precision health initiatives across the
continent. More recently, the company showcased life science
excellence with its extensive offering of lab automation and
sequencing products at ECCMID 2024 and announced a technical
assessment of the ABL DeepChek® assays by leading diagnostic
and medical software company, ABL Diagnostics, on its DNBSEQ-G400
and DNBSEQ-G99 platforms. Further verification and validation
studies of the DeepChek® assays will also be performed on the newly
launched DNBSEQ-E25.
"We have experienced positive growth and formed many valuable
partnerships in the region in recent years. Establishing our new
European headquarters will enable us to sustain this momentum to
empower more users," said Duncan Yu,
President at MGI. "We look forward to witnessing further
advancements by providing an optimal customer experience and
facilitating collaboration for greater omics access and
capabilities in Europe and
globally."
For more information about G400 Developer Program, please visit
here.
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to
MGI) is committed to building core tools and technologies that
drive innovation in life science. Our focus lies in research &
development, manufacturing, and sales of instruments, reagents, and
related products in the field of life science and
biotechnology. We provide real-time, multi-omics, and full
spectrum of digital equipment and systems for precision medicine,
agriculture, healthcare and various other industries. Founded in
2016, MGI has grown into a leader in life science, serving
customers across six continents and have established research,
manufacturing, training, and after-sales service facilities
globally. MGI stands out as one of the few companies capable of
independently developing and mass-producing clinical-grade gene
sequencers with varying throughput capacities, ranging from Gb to
Tb levels. With unparalleled expertise, cutting-edge products, and
a commitment to global impact, MGI continues to shape the
trajectory of life sciences into the future. To learn more, please
visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
Logo -
https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mgi-unveils-new-european-headquarters-in-berlin-germany-302163557.html